HCPCS code Q5118: Zirabev injection, per 10 mg2026 Medicare rate & RVUs

Reports bevacizumab-bvzr, marketed as Zirabev, for intravenous cancer treatment, with each billing unit representing 10 mg of the drug.

CMS RVU26DEffective Oct 1, 2026109 payment localities

Medicare rate · Q5118

Zirabev injection, per 10 mg

Office or facility?

Work RVUs
0
Total RVUs
0.00
Global days
XXX

National rate · 2026

—

Not priced in the facility setting.

See every locality for Q5118 →Billed by an NP, PA or therapist? →

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

Your location

Medicare pays by the payment locality where the service is performed.

On this page 10 sections
  1. Medicare rate
  2. What Q5118 covers
  3. By payment locality
  4. Rate map
  5. How it’s calculated
  6. Payment rules
  7. Similar codes
  8. Related codes
  9. Billing questions
  10. Sources

What Q5118 covers

Q5118 identifies bevacizumab-bvzr, the bevacizumab biosimilar marketed as Zirabev. Oncology clinicians use it by intravenous infusion in treatment regimens for certain advanced cancers, including colorectal, lung, kidney, cervical, ovarian, and recurrent brain cancers. The code represents the drug, not the infusion administration service, and is reported by the professional or facility furnishing the medication.

CMS assigns this code physician fee schedule status E, meaning it is excluded from that schedule; when Medicare covers the drug, payment is handled through another method. HCPCS classifies it as a Part B drug, generally priced from CMS’s quarterly Average Sales Price files when covered. Coverage is left to the Medicare contractor’s judgment. Each HCPCS unit represents 10 mg of bevacizumab-bvzr.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where Q5118 pays more and less

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

109 of 109 payment localities

Q5118 office and facility rates by payment locality
Payment localityOfficeFacility
AlabamaUnavailableUnavailable
AlaskaUnavailableUnavailable
ArizonaUnavailableUnavailable
ArkansasUnavailableUnavailable
Atlanta, GAUnavailableUnavailable
Austin, TXUnavailableUnavailable
Bakersfield, CAUnavailableUnavailable
Baltimore area, MDUnavailableUnavailable
Beaumont, TXUnavailableUnavailable
Brazoria, TXUnavailableUnavailable

Q5118 rates by state

Office rate range in each state. Select a state to see its payment localities.

Explore a state

Local rates. Clear comparisons.

Hover or focus a tile to see its rate range. Select it to open the state’s fee schedule.

View every state and territory as a table
Q5118 office rate range by state
State / territoryOffice rate rangeLocalities
AKNo published base rate1
ALNo published base rate1
ARNo published base rate1
AZNo published base rate1
CANo published base rate29
CONo published base rate1
CTNo published base rate1
DCNo published base rate1
DENo published base rate1
FLNo published base rate3
GANo published base rate2
GUNo published base rate1
HINo published base rate1
IANo published base rate1
IDNo published base rate1
ILNo published base rate4
INNo published base rate1
KSNo published base rate1
KYNo published base rate1
LANo published base rate2
MANo published base rate2
MDNo published base rate3
MENo published base rate2
MINo published base rate2
MNNo published base rate1
MONo published base rate3
MSNo published base rate1
MTNo published base rate1
NCNo published base rate1
NDNo published base rate1
NENo published base rate1
NHNo published base rate1
NJNo published base rate2
NMNo published base rate1
NVNo published base rate1
NYNo published base rate5
OHNo published base rate1
OKNo published base rate1
ORNo published base rate2
PANo published base rate2
PRNo published base rate1
RINo published base rate1
SCNo published base rate1
SDNo published base rate1
TNNo published base rate1
TXNo published base rate8
UTNo published base rate1
VANo published base rate2
VINo published base rate1
VTNo published base rate1
WANo published base rate2
WINo published base rate1
WVNo published base rate1
WYNo published base rate1

How the Q5118 rate is calculated

Each of Q5118’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

How the rate is built · Q5118

RVUs × geographic indexes × conversion factor

Office or facility?

Work0.00

0.00 RVUs× 1.000 GPCI

Practice expense0.00

0.00 RVUs× 1.000 GPCI

Malpractice0.00

0.00 RVUs× 1.000 GPCI

Adjusted RVUs

0.0000

Conversion factor

$33.4009

Medicare rate

$0.00

Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.

Payment rules and modifiers for Q5118

Q5118 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

Place of service · Q5118

Which rate does Medicare pay?

The POS code on the claim line (CMS-1500 box 24B).

POS 11 · non-facility rate · national

—

Q5118 isn’t priced in this setting.

Q5118 compared with similar codes

Compare codes · National

4 codes, side by side

Office or facility?

  • Q5118

    Zirabev injection, per 10 mg0 wRVU

    Not priced

  • Q5107

    Mvasi injection, per 10 mg0 wRVU

    Not priced

  • J9035

    Bevacizumab, per 10 mg0 wRVU

    Not priced

  • Q5126

    Alymsys injection, per 10 mg0 wRVU

    Not priced

How to choose

Q5107Mvasi injectionPer 10 mg
Both identify bevacizumab biosimilars with 10 mg units, but Q5107 is for Mvasi and Q5118 is for Zirabev. Use the code matching the product administered.
J9035BevacizumabPer 10 mg
J9035 identifies reference-product bevacizumab; Q5118 identifies the Zirabev biosimilar. The administered product determines the code.
Q5126Alymsys injectionPer 10 mg
Q5126 identifies Alymsys, another bevacizumab biosimilar. Q5118 is specific to Zirabev.

Q5118 billing questions

How many units should be reported?

Each unit represents 10 mg of bevacizumab-bvzr. Divide the reported drug quantity in milligrams by 10 to determine units.

Does Q5118 include the infusion service?

No. Q5118 identifies the drug; it does not describe infusion administration. Report the administration service separately when supported by the services performed.

When is Q5118 used instead of Q5107?

Q5118 identifies Zirabev (bevacizumab-bvzr); Q5107 identifies Mvasi (bevacizumab-awwb). Select the code for the specific product administered.

How does Medicare treat Q5118?

CMS excludes it from the physician fee schedule under status E. When covered, it is a Part B drug generally priced through CMS quarterly ASP files, with coverage left to the Medicare contractor’s judgment.

What should the record support?

Document the product administered, dose, route, and clinical indication so the reported drug and units can be substantiated.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates

Did this answer your question about what Q5118 pays?

Tell us what you were actually trying to work out. We’ll answer you directly, or build the page that does.

Fee sheets · Coming soon

Put Q5118 and the rest of your codes on one sheet

Your codes at your locality, with payer contracts beside Medicare.

Join the waitlist